The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD

J Ariana Noel; Ingrid Hougen; Manish M Sood

doi:10.3389/fneur.2022.823569

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD

Front Neurol. 2022 Jun 21:13:823569. doi: 10.3389/fneur.2022.823569. eCollection 2022.

Authors

J Ariana Noel^{1

2}, Ingrid Hougen^{1

2}, Manish M Sood¹

Affiliations

¹ Department of Nephrology, The Ottawa Hospital, Ottawa, ON, Canada.
² Postgraduate Medicine, University of Ottawa, Ottawa, ON, Canada.

Abstract

Impairment in cognition and decline in kidney function often converge in the aging individual with chronic kidney disease (CKD). Cognitive impairment (CI) may be preventable through modification of health behaviors and risk factors that contribute to the vascular disease burden. CKD patients often have multiple coexisting comorbid conditions contributing to vascular risk. These comorbidities include hypertension, diabetes, cerebrovascular disease, and cardiovascular disease. Emerging evidence suggests that the management and prevention of vascular risk factors and cardiovascular diseases may indirectly contribute to the prevention of CI in CKD. Sodium glucose transport protein 2 inhibitors (SGLT2i) are emerging as the standard of care for selected individuals with CKD, type 2 diabetes (T2DM), and heart failure with rapidly expanding indications being actively investigated. In this narrative review, we examine the intriguing hypothesis that SGLT2i demonstrate potential disease modifying properties in CI among individuals with CKD.

Keywords: SGLT2 inhibitor; albuminuria; chronic kidney disease; cognitive impairment; dementia.

Publication types

Review